Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

6 terminated/withdrawn out of 18 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

83%

10 of 12 completed trials have results

Key Signals

10 with results6 terminated

Enrollment Performance

Analytics

Phase 2
8(80.0%)
Phase 1
2(20.0%)
10Total
Phase 2(8)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT02711826Phase 1Completed

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Role: collaborator

NCT04066114Phase 1Completed

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Role: collaborator

NCT01428700Completed

Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C

Role: collaborator

NCT02495077Phase 2Completed

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Role: collaborator

NCT01790594Phase 2Terminated

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Role: collaborator

NCT01856257Phase 2Terminated

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Role: collaborator

NCT01278745Phase 2Terminated

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Role: collaborator

NCT03300882Completed

PREDICT Cytomegalovirus (CMV)

Role: collaborator

NCT02631720Completed

CLAD Phenotype Specific Risk Factors and Mechanisms

Role: collaborator

NCT01974999Completed

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

Role: collaborator

NCT01436305Phase 2Terminated

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

Role: collaborator

NCT01517984Phase 2Terminated

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Role: collaborator

NCT01289717Completed

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

Role: collaborator

NCT01516177Completed

Associating Renal Transplantation With the ITN Signature of Tolerance

Role: collaborator

NCT01672164Completed

Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

Role: collaborator

NCT00466804Completed

Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients

Role: collaborator

NCT01769443Phase 2Terminated

Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

Role: collaborator

NCT00307125Phase 2Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Role: collaborator

All 18 trials loaded